Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
McKesson
Baxter
McKinsey
Mallinckrodt

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR ESLICARBAZEPINE ACETATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Eslicarbazepine Acetate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00866775 ↗ Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Completed Sunovion Phase 3 2009-04-01 This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
NCT00898560 ↗ Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive Completed Bial - Portela C S.A. Phase 1 2008-09-01 The purpose of this study is to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) 800 mg once-daily (QD) affects the pharmacokinetics and tolerability of the components of a combined oral contraceptive (ethinyloestradiol and levonorgestrel).
NCT00900237 ↗ Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine Completed Bial - Portela C S.A. Phase 1 2008-11-01 This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to assess how these drugs are tolerated.
NCT00910247 ↗ Eslicarbazepine Acetate Monotherapy Long Term Study Completed Sunovion Phase 3 2009-08-01 This is a long term, open-label, safety extension study in subjects with partial onset seizures.
NCT00957047 ↗ Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy Completed Bial - Portela C S.A. Phase 3 2004-07-01 The primary objective of the study is to evaluate the efficacy of eslicarbazepine acetate once-daily at doses of 400 mg, 800 mg and 1200 mg compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a 12-week maintenance period. Patients who complete Part I may enter a 1-year open-label extension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Eslicarbazepine Acetate

Condition Name

Condition Name for Eslicarbazepine Acetate
Intervention Trials
Epilepsy 29
Partial Epilepsy 6
Bipolar I Disorder 3
Painful Diabetic Neuropathy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Eslicarbazepine Acetate
Intervention Trials
Epilepsy 38
Seizures 11
Epilepsies, Partial 10
Neuralgia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Eslicarbazepine Acetate

Trials by Country

Trials by Country for Eslicarbazepine Acetate
Location Trials
United States 151
Czech Republic 15
Portugal 14
Canada 9
Czechia 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Eslicarbazepine Acetate
Location Trials
Florida 8
California 6
Maryland 5
Louisiana 5
Kentucky 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Eslicarbazepine Acetate

Clinical Trial Phase

Clinical Trial Phase for Eslicarbazepine Acetate
Clinical Trial Phase Trials
Phase 4 2
Phase 3 14
Phase 2 10
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Eslicarbazepine Acetate
Clinical Trial Phase Trials
Completed 45
Terminated 4
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Eslicarbazepine Acetate

Sponsor Name

Sponsor Name for Eslicarbazepine Acetate
Sponsor Trials
Bial - Portela C S.A. 42
Sunovion 7
Whanin Pharmaceutical Company 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Eslicarbazepine Acetate
Sponsor Trials
Industry 51
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Johnson and Johnson
McKinsey
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.